|
ZC3H13 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62503344114384E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.10553796620161E-12 |
| Normal-vs-Stage2 |
6.32390000032679E-07 |
| Normal-vs-Stage3 |
8.77076189453874E-15 |
| Normal-vs-Stage4 |
1.18950405081364E-11 |
| Stage1-vs-Stage2 |
9.499600E-01 |
| Stage1-vs-Stage3 |
2.200100E-02 |
| Stage1-vs-Stage4 |
2.508000E-02 |
| Stage2-vs-Stage3 |
1.361380E-01 |
| Stage2-vs-Stage4 |
1.535200E-01 |
| Stage3-vs-Stage4 |
8.667800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.33226762955019E-15 |
| Normal-vs-AfricanAmerican |
1.159110E-04 |
| Normal-vs-Asian |
1.74490000004468E-07 |
| Caucasian-vs-AfricanAmerican |
3.836400E-01 |
| Caucasian-vs-Asian |
5.186200E-01 |
| AfricanAmerican-vs-Asian |
7.355800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.78586051397178E-12 |
| Normal-vs-Female |
1.77691195091256E-12 |
| Male-vs-Female |
3.225800E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.36639946421735E-10 |
| Normal-vs-Age(41-60Yrs) |
1.10245146345278E-13 |
| Normal-vs-Age(61-80Yrs) |
1.66588964845005E-12 |
| Normal-vs-Age(81-100Yrs) |
9.52720000000351E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.081040E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.523810E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.308780E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.726000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.018200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.916200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.509700E-02 |
| Classical-VS-Follicular |
8.600100E-02 |
| Classical-VS-Other |
2.229400E-01 |
| Classical-VS-Normal |
2.43793873977438E-12 |
| Tall-VS-Follicular |
5.474800E-01 |
| Tall-VS-Other |
6.947800E-01 |
| Tall-VS-Normal |
5.57270007917054E-10 |
| Follicular-VS-Other |
5.668600E-01 |
| Follicular-VS-Normal |
9.82259829029886E-11 |
| Other-VS-Normal |
6.436900E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.26041407813682E-13 |
| Normal-vs-N1 |
1.77109993337865E-10 |
| N0-vs-N1 |
4.376400E-01 |
|
|
